Seth Klarman's hedge fund firm Baupost Group has filed a 13G with the SEC regarding shares of Paratek Pharmaceuticals (PRTK). Per the filing, Baupost now owns 12.04% of the company with over 1.7 million shares.
This is a newly disclosed equity position for the firm and the filing was required due to activity on October 31st.
The firm has been active in that sector recently. Back in early November, Baupost also disclosed new positions in Atara Biotherapeutics (ATRA) and Forward Pharma (FWP), per 13G's filed with the SEC.
Per Google Finance, Paratek Pharmaceuticals is "a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience."
Friday, December 12, 2014
Baupost Group Discloses Paratek Pharmaceuticals Stake
blog comments powered by Disqus
